Subject(s)
Dysentery , Anti-Bacterial Agents/therapeutic use , Diarrhea/drug therapy , Diarrhea/etiology , HumansABSTRACT
INTRODUCTION: the current indicated first-line treatment for Helicobacter pylori (H. pylori) infection is the quadruple therapy with bismuth (Pylera®), or the quadruple concomitant therapy without bismuth. The triple therapy was abandoned due to its low eradication rates, partly derived from an increase in antibiotic resistance. The aim of this study was to compare the H. pylori eradication rates guided by antibiotic susceptibility testing (AST) versus Pylera®. METHODS: a specimen was taken prospectively for culture and antibiotic susceptibility testing (AST) from all patients diagnosed with H. pylori infection using gastroscopy, and they were randomized to receive triple therapy depending on the results of the AST, or quadruple therapy with Pylera®. The eradication rates of both groups were analyzed using fecal antigen. The adherence and side effects of the treatment were also analyzed. RESULTS: of the 108 patients with H. pylori infection, 55 received Pylera® and 53 AST-guided triple therapy. The eradication rates were 92.7 % with Pylera® and 90.6 % in the AST-guided group, and the difference was statistically significant. There were also no differences found in adherence or side effects. CONCLUSIONS: the treatment of H. pylori with AST-guided triple therapy is effective, especially in regions with high rates of antibiotic resistance.
Subject(s)
Helicobacter Infections , Helicobacter pylori , Anti-Bacterial Agents/therapeutic use , Bismuth/therapeutic use , Drug Therapy, Combination , Helicobacter Infections/drug therapy , Humans , Metronidazole/therapeutic use , Prospective Studies , Proton Pump Inhibitors/therapeutic use , Tetracycline/therapeutic use , Treatment OutcomeABSTRACT
No disponible
Subject(s)
Humans , Male , Adult , Colitis, Ulcerative/complications , Sweet Syndrome/etiology , Skin Diseases/etiology , Skin/pathology , Colitis, Ulcerative/drug therapy , Azathioprine/administration & dosage , Adrenal Cortex Hormones/therapeutic use , Sweet Syndrome/diagnosis , Biopsy , Colonoscopy/methods , Infliximab/therapeutic useABSTRACT
Sweet Syndrome or Acute Febrile Neutrophilic Dermatosis is an uncommon extraintestinal manifestation of inflammatory bowel disease, also related with other pathologies. Its diagnosis is anatomopathological and presents a good evolution with the treatment of the underlying disease.
Subject(s)
Colitis , Inflammatory Bowel Diseases , Sweet Syndrome , Humans , Sweet Syndrome/complications , Sweet Syndrome/diagnosisABSTRACT
No disponible
